WO2024189592 - SEPHIN1 AND RELATED COMPOUNDS FOR THE TREATMENT OF DISEASES AND DISORDERS AMENABLE TO TREATMENT BY AMPK ACTIVATION AND/OR CHOP INHIBITION
National phase entry:
Publication Number
WO/2024/189592
Publication Date
19.09.2024
International Application No.
PCT/IB2024/052531
International Filing Date
15.03.2024
Title **
[English]
SEPHIN1 AND RELATED COMPOUNDS FOR THE TREATMENT OF DISEASES AND DISORDERS AMENABLE TO TREATMENT BY AMPK ACTIVATION AND/OR CHOP INHIBITION
[French]
SEPHIN1 ET COMPOSÉS ASSOCIÉS POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES SUSCEPTIBLES D'ÊTRE TRAITÉS PAR ACTIVATION D'AMPK ET/OU INHIBITION DE CHOP
Applicants **
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
Inventors
GOJO, Satoshi
Priority Data
63/490,538
16.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2409 | |
| EPO | Filing, Examination, Granting | 13882 | |
| Japan | Filing, Examination, Granting | 2500 | |
| South Korea | Filing, Examination, Granting | 2829 | |
| USA | Filing, Examination, Granting | 5540 |
Total:
27,160
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods of treating diseases and disorders treatable by AMPK activation with sephin1 and related compounds, for example metabolic syndrome, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, sarcopenia, a neuromuscular disorder, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular diseases, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, an eye disease or disorder, ocular neovascularization, β-hemoglobinopathy, cancer, fibrosis, cancer cachexia, and mitochondrial disease.[French]
L'invention concerne des méthodes de traitement de maladies et de troubles susceptibles d'être traités par activation d'AMPK avec du séphin1 et des composés apparentés, par exemple le syndrome métabolique, la stéatose hépatique non alcoolique, la stéatohépatite non alcoolique (NASH), l'obésité, le diabète de type 2, l'insulinorésistance, l'intolérance au glucose, la douleur chronique, la sarcopénie, un trouble neuromusculaire, une insuffisance cardiaque, une hypertrophie cardiaque, une cardiomyopathie diabétique, une lésion de reperfusion cardiaque, une maladie rénale chronique, une maladie rénale polykystique, une néphropathie diabétique, des maladies cardiovasculaires, une maladie inflammatoire de l'intestin, une arthrite, une hypertension, une maladie vasculaire périphérique, un diabète insipide néphrogénique, un glaucome, une maladie ou un trouble oculaire, une néovascularisation oculaire, une β-hémoglobinopathie, un cancer, une fibrose, une cachexie cancéreuse et une maladie mitochondriale.